Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - January 2014

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Amiodarone -Tablets
Apixaban - 2.5 and 5 mg Tablets
Azacitidine - for Injection
Finasteride - Tablet, 1 mg
Ambrisentan - 5 mg and 10 mg Tablets
Boceprevir - 200 mg capsules
Carbamazepine - Chewable Tablets,
Carbamazepine - Oral Suspension
Carbamazepine - Extended-Release Tablets
Doripenem - for Injection
Dronedarone - 400 mg Tablets
Fosphenytoin
Lidocaine - (4% and 8%) and Dextrose 5% Injection
Linezolid - Oral Tablets, 400 mg and 600 mg
Linezolid - IV Injection, 2 mg/mL
Linezolid - for Oral Suspension, 100 mg/5mL
Losartan -25 mg, 50 mg, and 100 mg Tablets
Nevirapine - Extended-Release Tablets
Nevirapine - Tablets and Oral Suspension
Rivaroxaban - Tablets, 10 mg
Topiramate - Tablets (25mg, 50mg, 100mg, and 200mg)
Topiramate - Sprinkle Capsules (15mg, and 25mg)

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Ultimate Weight Loss Handbook: A Complete Guide to Achieving Your Goals
Stay Connected
Available on the Android Market Available on the App Store